RINVOQ (Upadacitinib) Emerging Drug Insight

“RINVOQ (Upadacitinib) Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about RINVOQ (Upadacitinib) for Crohn’s disease (CD) in the 7MM. A detailed picture of the RINVOQ (Upadacitinib) for Crohn’s disease (CD) in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the RINVOQ (Upadacitinib) for Crohn’s disease (CD). The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the RINVOQ (Upadacitinib) market forecast, analysis for Crohn’s disease (CD) in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Crohn’s disease (CD).

Drug Summary

RINVOQ, also known by the generic name Upadacitinib (ABT-494), is a JAK1 selective inhibitor being investigated by AbbVie to treat Crohn's disease. JAKs are intracellular enzymes that transmit signals arising from cytokine or growth factor receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Within the signaling pathway, JAKs phosphorylate and activate Signal Transducers and Activators of Transcription (STATs), which modulate intracellular activity, including gene expression. Upadacitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs.

JAK enzymes transmit cytokine signaling through their pairing (e.g., JAK1/JAK2, JAK1/JAK3, JAK1/TYK2, JAK2/JAK2, and JAK2/TYK2). In a cell-free, isolated enzyme assay, upadacitinib had greater inhibitory potency at JAK1 and JAK2 relative to JAK3 and TYK2. In human leukocyte cellular assays, upadacitinib inhibited cytokine-induced STAT phosphorylation mediated by JAK1 and JAK1/JAK3 more potently than JAK2/JAK2-mediated STAT phosphorylation. However, the relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known.

Scope of the Report

The report provides insights into:

•  A comprehensive product overview including the RINVOQ (Upadacitinib) description, mechanism of action, dosage and administration, research and development activities in Crohn’s disease (CD).
•  Elaborated details on RINVOQ (Upadacitinib) regulatory milestones and other development activities have been provided in this report.
•  The report also highlights the RINVOQ (Upadacitinib) research and development activity in Crohn’s disease (CD) in detail across the United States, Europe and Japan.
•  The report also covers the patents information with expiry timeline around RINVOQ (Upadacitinib).
•  The report contains forecasted sales of RINVOQ (Upadacitinib) for Crohn’s disease (CD) till 2032.
•  Comprehensive coverage of the late-stage emerging therapies for Crohn’s disease (CD).
•  The report also features the SWOT analysis with analyst views for RINVOQ (Upadacitinib) in Crohn’s disease (CD).

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

RINVOQ (Upadacitinib) Analytical Perspective by DelveInsight

• In-depth RINVOQ (Upadacitinib) Market Assessment

This report provides a detailed market assessment of RINVOQ (Upadacitinib) in Crohn’s disease (CD) in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

• RINVOQ (Upadacitinib) Clinical Assessment

The report provides the clinical trials information of RINVOQ (Upadacitinib) in Crohn’s disease (CD) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

•  In the coming years, the market scenario for Crohn’s disease (CD) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
•  The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence RINVOQ (Upadacitinib) dominance.
•  Other emerging products for Crohn’s disease (CD) are expected to give tough market competition to RINVOQ (Upadacitinib) and launch of late-stage emerging therapies in the near future will significantly impact the market.
•  A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of RINVOQ (Upadacitinib) in Crohn’s disease (CD).
•  Our in-depth analysis of the forecasted sales data of RINVOQ (Upadacitinib) from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the RINVOQ (Upadacitinib) in Crohn’s disease (CD).

Key Questions

•  What is the product type, route of administration and mechanism of action of RINVOQ (Upadacitinib)?
•  What is the clinical trial status of the study related to RINVOQ (Upadacitinib) in Crohn’s disease (CD) and study completion date?
•  What are the key collaborations, mergers and acquisitions, licensing and other activities related to the RINVOQ (Upadacitinib) development?
•  What are the key designations that have been granted to RINVOQ (Upadacitinib) for Crohn’s disease (CD)?
•  What is the forecasted market scenario of RINVOQ (Upadacitinib) for Crohn’s disease (CD)?
•  What are the forecasted sales of RINVOQ (Upadacitinib) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
•  What are the other emerging products available in Crohn’s disease (CD) and how are they giving competition to RINVOQ (Upadacitinib) for Crohn’s disease (CD)?
•  Which are the late-stage emerging therapies under development for the treatment of Crohn’s disease (CD)?